Graham Capital Management L.P. Has $221,000 Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

Graham Capital Management L.P. lifted its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 59.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 28,542 shares of the biotechnology company’s stock after purchasing an additional 10,677 shares during the period. Graham Capital Management L.P. owned 0.06% of REGENXBIO worth $221,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. D. E. Shaw & Co. Inc. lifted its holdings in REGENXBIO by 15.0% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 63,377 shares of the biotechnology company’s stock valued at $490,000 after buying an additional 8,271 shares during the period. Deutsche Bank AG raised its holdings in shares of REGENXBIO by 8.5% during the fourth quarter. Deutsche Bank AG now owns 200,375 shares of the biotechnology company’s stock valued at $1,549,000 after purchasing an additional 15,722 shares during the period. Corton Capital Inc. acquired a new position in shares of REGENXBIO during the fourth quarter valued at about $103,000. Cubist Systematic Strategies LLC acquired a new position in shares of REGENXBIO during the fourth quarter valued at about $2,793,000. Finally, Brevan Howard Capital Management LP acquired a new position in shares of REGENXBIO during the fourth quarter valued at about $318,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

Insider Activity at REGENXBIO

In other REGENXBIO news, Director Kenneth T. Mills sold 20,602 shares of the stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $7.91, for a total value of $162,961.82. Following the sale, the director now directly owns 475,103 shares in the company, valued at $3,758,064.73. This represents a 4.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 12.79% of the stock is currently owned by corporate insiders.

REGENXBIO Trading Up 2.9%

Shares of RGNX stock opened at $8.89 on Monday. The stock has a market capitalization of $445.92 million, a P/E ratio of -1.77 and a beta of 1.11. The firm’s 50 day moving average is $7.54 and its 200 day moving average is $7.97. REGENXBIO Inc. has a 12 month low of $5.04 and a 12 month high of $16.25.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.29). The business had revenue of $89.01 million for the quarter, compared to analysts’ expectations of $105.35 million. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. On average, equities analysts predict that REGENXBIO Inc. will post -4.84 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on RGNX shares. Chardan Capital reissued a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a research report on Thursday, March 20th. Leerink Partners set a $24.00 target price on shares of REGENXBIO in a research report on Tuesday, March 18th. StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, March 7th. HC Wainwright decreased their target price on shares of REGENXBIO from $36.00 to $34.00 and set a “buy” rating for the company in a research report on Monday, March 17th. Finally, Raymond James started coverage on shares of REGENXBIO in a research report on Friday, February 7th. They set an “outperform” rating and a $27.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, REGENXBIO currently has an average rating of “Moderate Buy” and an average target price of $31.63.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.